NX-5948 for Healthy Subjects

Recruiting in Palo Alto (17 mi)

Age: 18 - 65

Sex: Male

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Nurix Therapeutics, Inc.

No Placebo Group

Trial Summary

What is the purpose of this trial?This is a Phase 1, 2-part double-blinded (with respect to NX-5948/placebo), placebo-controlled study. Part 1 is a randomized, 3 period cross-over food-effect (FE) and drug-drug interaction (DDI) study. Part 2 is a single-period PK evaluation study.

Eligibility Criteria

This trial is for healthy adults. Specific details about who can join are not provided, but typically participants should have no significant health issues and be willing to follow the study procedures.

Inclusion Criteria

I am a healthy man aged between 18 and 55.

Exclusion Criteria

I have a history of severe allergies or serious heart, adrenal, or skin conditions.

Participant Groups

The study tests NX-5948's effects with food and other drugs in the body (pharmacokinetics). It has two parts: one where subjects take NX-5948 or placebo randomly with different meal conditions, and another that measures how the drug moves through and leaves the body.

3Treatment groups

Experimental Treatment

Group I: Part 2: NX-5948 PKExperimental Treatment1 Intervention

Experimental: Part 2: NX-5948 PK NX-5948 or placebo administered 2 doses given 12 hours apart under fasted conditions

Group II: Part 1: Sequence 2 (Treatment B, A, C)Experimental Treatment2 Interventions

Period 1: NX-5948 or placebo administered under fed conditions Period 2: NX-5948 or placebo administered under fasted conditions Period 3: Fluconazole and single dose of NX-5948/placebo coadministered on Day 4

Group III: Part 1: Sequence 1 (Treatment A, B, C)Experimental Treatment2 Interventions

Period 1: NX-5948 or placebo administered under fasted conditions Period 2: NX-5948 or placebo administered under fed conditions Period 3: Fluconazole and single dose of NX-5948/placebo coadministered on Day 4